News flow potential short to mid term (2022) share price catalyst. Not in order.
FDA Fast Track to phase 2 human trials CTAP.
Non Equity funding arrangement. (Likely Trading Halt)
Small Trial 1 (5 day course BIT225) outside US in Large Covid Population.
Large FDA trial in US possible 30 cohort (8kg BIT225)
FDA approval 9-12months
Buyout possible anytime.
HIV current studies Immune response combined with ART mid 2022.
Current SP 9c
chart daily, page-2386
Add BIT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.0¢ |
Change
-0.001(4.76%) |
Mkt cap ! $18.04M | |||
| Open | High | Low | Value | Volume |
| 2.1¢ | 2.1¢ | 2.0¢ | $12.00K | 600.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 972631 | 1.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.1¢ | 199783 | 1 |
View Market Depth
| Last trade - 14.33pm 01/11/2024 (20 minute delay) ? |
| BIT (ASX) Chart |